Title: Effectiveness and safety of laropiprant on niacin-induced flushing.
Journal: The American journal of cardiology20120915
Title: Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
Journal: Metabolic syndrome and related disorders20120801
Title: Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
Journal: The European journal of health economics : HEPAC : health economics in prevention and care20120601
Title: Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions20120601
Title: Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Journal: Expert opinion on pharmacotherapy20120601
Title: Bullous drug eruption secondary to nicotinic acid/laropiprant.
Journal: Annals of the Academy of Medicine, Singapore20120301
Title: Safety and tolerability of extended-release niacin with laropiprant.
Journal: Expert opinion on drug safety20120101
Title: Lipid disorders in elderly hypertensive patients.
Journal: International journal of hypertension20120101
Title: Attenuation of niacin-induced prostaglandin D(2) generation by omega-3 fatty acids in THP-1 macrophages and Langerhans dendritic cells.
Journal: Journal of inflammation research20120101
Title: Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
Journal: Journal of clinical lipidology20120101
Title: Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.
Journal: PloS one20120101
Title: Familial hypercholesterolemia: present and future management.
Journal: Current cardiology reports20111201
Title: Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).
Journal: Annals of clinical biochemistry20111101
Title: Progress in HDL-based therapies for atherosclerosis.
Journal: Current atherosclerosis reports20111001
Title: Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.
Journal: Current vascular pharmacology20110701
Title: Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation20110601
Title: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Journal: European heart journal20110601
Title: The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
Journal: The Israel Medical Association journal : IMAJ20110601
Title: Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
Journal: International journal of clinical practice20110401
Title: The causes and consequences of low levels of high density lipoproteins in patients with diabetes.
Journal: Diabetes & metabolism journal20110401
Title: Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
Journal: Journal of clinical pharmacology20110301
Title: The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
Journal: Platelets20110101
Title: Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study.
Journal: International journal of hypertension20110101
Title: Treating statin-intolerant patients.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20110101
Title: Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Journal: Journal of clinical lipidology20110101
Title: Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.
Journal: Clinical Medicine Insights. Cardiology20110101
Title: Biological roles and therapeutic potential of hydroxy-carboxylic Acid receptors.
Journal: Frontiers in endocrinology20110101
Title: Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
Journal: Journal of clinical pharmacology20101101
Title: Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease.
Journal: Current cardiology reports20101101
Title: Induction of prostaglandin D2 through the p38 MAPK pathway is responsible for the antipruritic activity of sertaconazole nitrate.
Journal: The Journal of investigative dermatology20101001
Title: HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD20101001
Title: Management of hypertriglyceridemia in the diabetic patient.
Journal: Current diabetes reports20100801
Title: Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
Journal: Journal of clinical pharmacology20100701
Title: Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Journal: Expert opinion on pharmacotherapy20100701
Title: [Hyperlipoproteinaemia and dyslipoproteinaemia II. Therapy: non-pharmacological and pharmacological approaches].
Journal: Vnitrni lekarstvi20100701
Title: Niacin and laropiprant.
Journal: Drugs of today (Barcelona, Spain : 1998)20100601
Title: Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease.
Journal: The Journal of biological chemistry20100521
Title: Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Journal: International journal of clinical practice20100501
Title: Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
Journal: Clinical journal of the American Society of Nephrology : CJASN20100401
Title: A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Journal: Expert opinion on investigational drugs20100301
Title: Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects.
Journal: Prescrire international20100201
Title: Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Journal: European heart journal20100101
Title: Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.
Journal: Platelets20100101
Title: Niacin, an old drug with new perspectives for the management of dyslipidaemia.
Journal: Acta clinica Belgica20100101
Title: Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.
Journal: Therapeutics and clinical risk management20100101
Title: Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
Journal: Journal of clinical lipidology20100101
Title: Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Journal: Journal of clinical lipidology20100101
Title: Low high-density lipoprotein cholesterol: current status and future strategies for management.
Journal: Vascular health and risk management20100101
Title: Treatment of dyslipidemia in patients with type 2 diabetes.
Journal: Lipids in health and disease20100101
Title: Recent advances in preventing cardiovascular disorders by managing lipid levels.
Journal: F1000 medicine reports20100101
Title: High density lipoproteins-based therapies for cardiovascular disease.
Journal: Journal of cardiovascular disease research20100101
Title: Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.
Journal: Drug, healthcare and patient safety20100101
Title: Current strategies and recent advances in the therapy of hypercholesterolemia.
Journal: Atherosclerosis. Supplements20091229
Title: What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Journal: Current opinion in lipidology20091201
Title: Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Journal: Journal of clinical pharmacology20091201
Title: Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
Journal: The Journal of allergy and clinical immunology20091101
Title: Mechanisms of flushing due to niacin and abolition of these effects.
Journal: Journal of clinical hypertension (Greenwich, Conn.)20091101
Title: The mechanism and mitigation of niacin-induced flushing.
Journal: International journal of clinical practice20090901
Title: Extended-release niacin (nicotinic acid)/laropiprant.
Journal: Drugs20090820
Title: Nephropathy and other topics.
Journal: Diabetes care20090801
Title: Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Journal: The American journal of cardiology20090701
Title: Discovery of potent and selective DP1 receptor antagonists in the azaindole series.
Journal: Bioorganic & medicinal chemistry letters20090415
Title: Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Journal: Journal of clinical pharmacology20090401
Title: Does nicotinic acid (niacin) lower blood pressure?
Journal: International journal of clinical practice20090101
Title: Niacin: an old drug rejuvenated.
Journal: Current atherosclerosis reports20090101
Title: A review of trials evaluating nonstatin lipid-lowering therapies.
Journal: Current atherosclerosis reports20090101
Title: High-density lipoprotein cholesterol: current perspective for clinicians.
Journal: Angiology20090101
Title: Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Journal: Clinical therapeutics20090101
Title: Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.
Journal: American journal of therapeutics20090101
Title: Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Journal: Vascular health and risk management20090101
Title: Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Journal: American journal of therapeutics20090101
Title: Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
Journal: Cardiology20090101
Title: Drug-drug noninteractions.
Journal: Cardiovascular therapeutics20090101
Title: Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
Journal: Cardiovascular therapeutics20090101
Title: Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Journal: American journal of therapeutics20090101
Title: Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Journal: Vascular health and risk management20090101
Title: Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.
Journal: Journal of clinical lipidology20090101
Title: Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Journal: International journal of clinical practice20081201
Title: Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Journal: Cardiology clinics20081101
Title: Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Journal: Vascular health and risk management20081001
Title: Nicotinic acid: recent developments.
Journal: Current opinion in cardiology20080701
Title: Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
Journal: Clinical pharmacology and therapeutics20080601
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20080601
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20080501
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20080401
Title: Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Journal: The American journal of cardiology20080301
Title: Gateways to clinical trials. July-August 2008.
Journal: Methods and findings in experimental and clinical pharmacology20080101
Title: Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides.
Journal: Current topics in medicinal chemistry20080101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20071201
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20071001
Title: Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals20070701
Title: Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
Journal: Clinical pharmacology and therapeutics20070601
Title: Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.
Journal: Bioorganic & medicinal chemistry letters20070601
Title: The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys.
Journal: Xenobiotica; the fate of foreign compounds in biological systems20070501
Title: Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).
Journal: Journal of medicinal chemistry20070222
Title: Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals20070201
Title: In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.
Journal: Bioorganic & medicinal chemistry letters20070115
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20070101
Title: Body temperatures and heart rates of laboratory rats and Belding squirrels (Spermophilus beldingi) during behavioral thermoregulation.
Journal: Comparative biochemistry and physiology. A, Comparative physiology19751201
